News

Immatics appoints Thomas Ulmer as Chief Financial Officer

Details

Immatics today announced the appointment of Thomas Ulmer as Chief Financial Officer, effective April 1st, 2018. Thomas Ulmer joins Immatics from the Merck Group, where he is currently Chief Financial Officer of the Allergopharma Business Unit. 

Themis raises EUR 10 million in Series C financing to advance clinical pipeline

Details

Themis announced the close of a Series C financing round led by Global Health Investment Fund (GHIF) as a new investor in the company. Glenn Rockman, Partner at GHIF, will join Themis’ Supervisory Board. The Series C proceeds will be used to advance Themis’ clinical and pre-clinical vaccine development programs. 

Themis presents Phase II interim results for Chikungunya vaccine candidate at ASTMH 2017

Details

Themis announced positive interim results from an ongoing phase 2 clinical study designed to demonstrate safety and immunogenicity of MV-CHIK, its live attenuated prophylactic vaccine candidate for chikungunya fever. The data will be presented for the first time at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) in Baltimore, MA, USA. 

  1. Ambu acquires Wellington Partners portfolio company invendo medical
  2. Immatics receives $58 million in financing to develop T-cell receptor based immunotherapies
  3. Immatics initiates first Phase I clinical trial of ACTengine® approach in patients with advanced solid cancers
  4. Wellington featured in BioCentury
© Wellington Partners, 2019.